Adjuvant capecitabine in combination with docetaxel and cyclophosphamide versus anthracycline plus docetaxel and cyclophosphamide regimen in women with high‐risk, HER2‐negative breast cancer: An open‐label, randomized controlled trial
Abstract Background The standard adjuvant chemotherapy for early‐stage, high‐risk breast cancer includes anthracyclines and taxanes. While anthracycline‐based regimens have proven effective in human epidermal growth factor receptor 2 (HER2)‐positive breast cancer, their efficacy may be reduced in HE...
Enregistré dans:
| Auteurs principaux: | , , , , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Wiley
2025-09-01
|
| Collection: | Cancer Communications |
| Sujets: | |
| Accès en ligne: | https://doi.org/10.1002/cac2.70041 |
| Tags: |
Pas de tags, Soyez le premier à ajouter un tag!
|